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Background: Many studies support the hypothesis that specific microRNA (miRNA) expression in various human
cancers including hepatocarcinogenesis is closely associated with diagnosis and prognosis. In hepatocellular
carcinoma (HCC), malignancy level is related to the degree of histological differentiation.
Methods: In order to establish a novel biomarker that can determine the degree of malignancy and forecast
patient prognosis, we performed a microarray analysis to investigate the miRNA expression profiles in 110 HCC
which were comprised of 60 moderately, 30 poorly, and 20 well differentiated HCC.
Results: We found that the expression of 12 miRNAs varied significantly according to the degree of histological
differentiation. Particularly, miR-18b expression in poorly differentiated HCC was significantly higher than in well
differentiated HCC. Based on miRanda and Targetscan target search algorithms and Argonaute 2
immunoprecipitation study, we noted that miR-18b can control the expression of trinucleotide repeat containing
6B (TNRC6B) as a target gene. Additionally, in two hepatoma cell lines, we found that over-expression of miR-18b or
down-regulation of TNRC6B accelerated cell proliferation and loss of cell adhesion ability. Finally, we observed that
after surgical resection, HCC patients with high miR-18b expression had a significantly shorter relapse-free period
than those with low expression.
Conclusions: miR-18b expression is an important marker of cell proliferation and cell adhesion, and is predictive of
clinical outcome. From a clinical point of view, our study emphasizes miR-18b as a diagnostic and prognostic
marker for HCC progression.
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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of death from cancer worldwide [1]. The most
frequent etiologies of HCC are chronic hepatitis B and C
(CHB, CHC), and alcoholic liver disease [2]. Although
recent advances in functional genomics provide a deeper
understanding of hepatocarcinogenesis [3,4], the molecu-
lar pathogenesis of HCC remains rather unclear. Indeed,
the clinical heterogeneity of HCC and the lack of good* Correspondence: m2079633@med.osaka-cu.ac.jp
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reproduction in any medium, provided the ordiagnostic markers and treatment strategies have rendered
this disease a major challenge.
Cell differentiation and drug-induced differentiation
of tumor cells into benign or normal cells, are important
targets for anticancer chemotherapy [5]. Cellular differ-
entiation in HCC progresses from non-tumor tissue to
well-differentiated cancerous tissue [6]. As such, along
with other clinical factors, the degree of histological dif-
ferentiation in HCC is closely related to clinical course.
Tumor-free survival rates have shown that moderately
or poorly differentiated HCC is a significant risk factor
for recurrence [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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control of numerous biological processes, such as devel-
opment, differentiation, proliferation and apoptosis [8].
Altered miRNA expression has been observed in a large
variety of HCC and a correlation has been found between
miRNA expression and histological differentiation [9,10].
The expression level of miR-26 was associated with
hepatocarcinogenesis and response of interferon therapy
[11]. Moreover, the hepatic miRNA expression pattern
that existed in CHC patients before anti-viral therapy is
associated with the outcome of pegylated interferon and
rivabirin combination therapy [12]. Additionally, aberrant
expression of miRNAs particularly, miR-199a, miR-199a*,
miR-200a, and miR-200b has been closely associated with
the progression of liver fibrosis in both human and mouse
[13]. Recently the expression level of miR-122 was associ-
ated with not only hepatocarcinogenesis but liver homeo-
stasis and essential liver metabolism [14,15]. Among
others, miR-18 which is intimately associated with the
occurrence and progression of different types of cancer
have also been implicated [16]. In other research, miRNA
expression profile was associated with vascular invasion,
the value of alpha-fetoprotein, and large tumor size [17].
Given miRNA’s importance in liver pathology, we
sought to evaluate the diagnostic and prognostic signifi-
cance of miRNA expression in HCC and to determine the
functional implication of miRNAs deregulation in the
development of liver cancer. As a part of this process, we
profiled miRNA expression according to the degree of
histological differentiation of HCC, and established a
novel biomarker for determining HCC malignancy degree.
Using our findings, we will show that miR-18b repression
in HCC correlates with clinically relevant parameters such
as histological differentiation status, and that the loss of
miR-18b expression correlates with distinct gene expres-
sion profiles characteristic of tumor progression (that is,




110 hepatocellular carcinoma tissue samples were ob-
tained by surgical resection (Additional file 1: Table S1).
All patients or their guardians provided written informed
consent, and Osaka City University, Ogaki Municipal Hos-
pital and Kyoto University Graduate School and Faculty of
Medicine’s Ethics Committee approved all aspects of this
study in accordance with the Helsinki Declaration.
RNA preparation and miRNA microarray
Total RNA from cell lines or tissue samples was prepared
using a mirVana miRNA extraction Kit (Ambion, Austin,
TX, USA) according to the manufacturer’s instruction. To
detect miRNA, 100 ng of RNA was labeled and hybridizedusing the Human microRNA Microarray Kit (Rel 12.0)
(Agilent Technologies, CA, USA) according to manu-
facturer’s protocol for use with Agilent microRNA
microarrays Version 1.0. Hybridization signals were de-
tected with Agilent DNA microarray scanner G2505B and
the scanned images were analyzed using Agilent feature ex-
traction software (v9.5.3.1). Data were analyzed using
GeneSpring GX 7.3.1 software (Agilent Technologies) and
normalized as follows: (i) Values below 0.01 were set to
0.01. (ii) Each measurement was divided by the 75th per-
centile of all measurements from the same species. All
data were deposited in NCBI’s Gene Expression Omnibus
and are accessible through GEO Series accession number
GSE31164.
Real-time qPCR for human miRNA
To detect miRNA level by real-time qPCR, TaqManW
microRNA assay (Applied Biosystems) was used to
quantify the relative expression level of miR-18b (assay
ID. 002217); U18 (assay ID. 001204) was used as an in-
ternal control. cDNA was synthesized using the Taqman
miRNA RT Kit (Applied Biosystems). Total RNA (10
ng/ml) in 5ml of nuclease free water was added to 3 ml
of 5× RT primer, 10× 1.5 μl of reverse transcriptase
buffer, 0.15 μl of 100 mM dNTP, 0.19 μl of RNase
inhibitor, 4.16 μl of nuclease free water, and 50U of
reverse transcriptase in a total volume of 15 μl. The
reaction was performed in triplicate for 30 min at 16°C,
30 min at 42°C, and 5 min at 85°C. Chromo 4 detector
(BIO-RAD) was used to detect miRNA expression.
Cell lines and miRNA or DNA transfection
The human hepatoma cell lines Huh-7, Li7 and human
embryonal kidney cells lines 293FT were obtained from
Japanese Collection of Research Bioresources cell bank.
Cells were maintained in D-MEM (Invitrogen, Carlsbad,
CA, USA) with 10% fetal bovine serum and plated in
6-well plates the day before transfection, then grown to
70% confluence. Cells were transfected with 12.5 pmol/l of
SilencerW negative control siRNA (Ambion), siTNRC6B s;
5′-gggacaaggaggaaagaaatt-3′, as; 5′-uuucuuuccuccuu
guccctt-3′ (Hokkaido System Science, Sapporo, Japan)
or double-stranded mature miR-18b (Hokkaido System
Science) using lipofectamine RNAiMAX (Invitrogen).
Cells were also transfected with 1 μg/μl of negative con-
trol cDNA empty vector or total TNRC6B expression
vector (Addgene) using FugeneW (Roche). TNRC6B
complete plasmid set was obtained from the non-profit
repository AddGene (http://www.addgene.com). Cells
were harvested 48 hr after transfection.
Real-time qPCR
cDNA was synthesized using the Transcriptor High
Fiderity cDNA synthesis Kit (Roche, Basel, Switzerland).
Total RNA (2 μg) in 10.4 μl of nuclease free water was
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for 10 min at 65°C. The denatured RNA mixture was
added to 4 μl of 5× reverse transcriptase buffer, 2 μl of
10 mM dNTP, 0.5 μl of 40U/μl RNase inhibitor, and 1.1
μl of reverse transcriptase (FastStart Universal SYBR
Green Master Roche) in a total volume of 20 μl. The
reaction was run in triplicate for 30 min at 50°C (cDNA
synthesis), and five min at 85°C (enzyme denaturation).
Chromo 4 detector (BIO-RAD, Hercules, CA, USA) was
used to detect mRNA expression. The primer sequences
was as follows TNRC6B s; 5′-acaagtgacaggagcgctgctg-3′,
as; 5′- ccatgtcagacccgtctacaat-3′, and β-actin s; 5′-
ccactggcatcgtgatggac-3′, as; 5′-tcattgccaatggtgatgacct-3′.
Assays were performed in triplicate, and the expression
levels of target genes were normalized to the expression
of the β-actin gene (internal control), as quantified by
real-time qPCR.Transient transfection and luciferase assay
To generate the TNRC6B 3′-UTR luciferase reporter
vectors, the TNRC6B 3′-UTR segments were generated
(Additional file 1: Table S3) and inserted into the
pMIR-REPORT Luciferase vector between SpeI and
HindIII sites (Ambion). Wild and mutant type reporter
vectors with miR-18b complementary sites were con-
firmed by sequencing. Huh7.5 cells (5×104 cell/well)
were transfected into 24-well dishes with DMRIE-C
(Invitrogen), 10pmol of double stranded mature miR-
18b, Antisense oligonucleotide of miR-18b, or negative
control of RNA and 0.25 μg wild or mutant type re-
porter vector. After 48 h, the transfected cells were
harvested and lysed, and their luciferase activity was
measured with a Dual-Luciferase Reporter Assay Sys-
tem kit (Promega). The experiments were repeated at
least three times.Co-immunoprecipitation with Ago2
A cell lysate from RNA-induced silencing complex
(RISC), was collected using microRNA Isolation Kit, Hu-
man Ago2 (Wako, Osaka, Japan) according to the manu-
facturer’s instruction. Briefly, 48 hr after transfection
with 12.5 pmol/L of double stranded mature miRNA,
5×106 cells in 6 cm dish were washed with PBS and
harvested by trypsinization. The cell pellet was re-
suspended with the gentle pipetting in 1ml of cell lysisTable 1 Clinical background
histological differentiation number (gender) age (aver
well 20 (M:15, F:5) 66.5+/−
moderately 60 (M:51, F:9) 66.5+/−
poorly 30 (M:27, F:3) 67.7+/−
Abbreviation: NBNC, neither HBV nor HCV infection, NI, no information, CH, chronicbuffer (microRNA Isolation Kit). The cell suspension
was incubated for 10 minutes on ice, and was then
centrifuged at a force of 20000 g for 20 minutes at 4°C.
The cells were suspended in PBS and mixed with beads
conjugated human Argonaute2 (hAgo2) monoclonal
antibody for 2 hr at 4°C. RNA from Ago2-
immunoprecipitation fraction was then extracted using
mirVana miRNA extraction kit.
In situ hybridization for miR-18b and
immunohistochemistry for TNRC6B
Eight paraffin-embedded tissue samples (case 64, 108,
248, 261, 274, 277, 310 and 333) were used (Additional
file 1: Table S1). We generated both a locked nucleic
acid (LNA) −modified probe for miR-18b (5′- taaggtgca
tctagtgcagttag-3′) and a scrambled negative control se-
quence (5′-gtgtaacacgtctatacgccca-3′: miRCURY-LNA
detection probe, Exiqon, Vedbaek, Denmark). In situ
hybridization utilized a RiboMap in situ hybridization
kit (Roche Diagnostic) on a Ventana Discovery automated
in situ hybridization instrument (Roche Diagnostic). For
immunohistochemistry of FFPE sections, we used the
Ventana HX System Benchmark (Roche Diagnostic).
TNRC6B antibody (HPA003180) was purchased from
Sigma-Aldrich, St. Louis, MO, USA.
Estimating positive staining for miR-18b using in situ
hybridization and immunostaining of TNRC6B
Positive in situ hybridization staining and immunostaining
were interpreted semi-quantitatively by assessing the in-
tensity and extent of staining on the entire tissue sections
observed on the slides, as described previously [18].
Cell proliferation assay
The cell proliferation assay was performed using XTTW
Cell Proliferation Assay Kit (Roche). Briefly, huh7 and
Li7 cells (5×105 cells/ml) were spread into 96-well
dishes. 12.5 pmol/l of double stranded mature miR-18b,
2′-O-methylated antisense oligonucleotide (ASO) of
miR-18b (Hokkaido System Science), siRNA for TNRC6B
(Hokkaido System Science) and SilencerW negative control
siRNA (Ambion), were transfected with lipofectamine
RNAiMAX (Invitrogen). 2 ug of plasmids containing
the TNRC6B (Addgene), or empty vector pcDNA3
(Invitrogen) was transfected with FuGENE 6 (Roche).
After 24 or 72 hr of transfection, cells were washedage) viral infection background of HCC
6.3 HBV:2, HCV:18 CH:7, LC:12, NI:1
8.7 HBV:7, HCV:49, NBNC:3, NI:1 CH:25, LC:30, NI:5
5.4 HBV:0, HCV:20 CH:14, LC:16
hepatitis, LC, liver cirrhosis.
Table 2 Significantly different expression of miRNA
according to the histological differentiation
histological differentiation
miRNA poor moderately well p-value
hsa-miR-455-3p 0.887 1.000 1.033 0.0012
hsa-miR-221 0.993 1.000 0.800 0.0027
hsa-miR-1914* 0.925 1.000 1.196 0.0025
hsa-miR-18b 1.175 1.000 0.761 0.0064
hsa-miR-100 0.850 1.000 1.000 0.0221
hsa-miR-215 0.954 1.000 1.026 0.0103
hsa-miR-122* 0.905 1.000 1.015 0.0006
hsa-let-7b 0.927 1.000 1.022 0.0178
hsa-miR-22 0.885 1.000 1.010 0.0026
hsa-miR-99a 0.877 1.000 0.976 0.0047
hsa-miR-18a 1.127 1.000 0.893 0.0071
hsa-miR-423-5p 1.087 1.000 0.806 0.0045
The relative expression value of each miRNAs which set moderately


































Figure 1 Process of retrieving target genes of several miRNAs. A) Hom
of the sequence between miR-18b and TNRC6B gene by miRanda algorith
TNRC6B expression when miRNA is over-expressed or suppressed are show
significant difference (p < 0.05). C) Transfection of reporter vectors with eith
18b. The data shown are means ± SD of three independent experiments. A
confirmation by argonaute 2 (Ago2) immunoprecipitation (IP). When miR-1
abundantly contained in RISC. TNRC6B RNA was measured by real-time qP
shown are means ± SD of three independent experiments. Asterisk indicat
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http://www.biomedcentral.com/1471-2407/13/99twice with PBS, 50ul of XTT labeling mixture was
added, and then cells were incubated in a humidified at-
mosphere for 6 hr at 37°C. After incubation, the absorb-
ance of samples was measured using an ELISA reader at
450–500 nm against a reference wavelength of 650 nm.
Cell adhesion assay
The cell adhesion assay was carried out using VybrantW
Cell Adhesion Assay Kit (Invitrogen). Briefly, transfec-
tion procedure was same as the cell proliferation assays.
After 24 or 72 hr of transfection, cells were washed
twice with PBS then re-suspended in serum free D-
MEM and incubated with 5 μl of the calcein AM stock
solution at 37°C for 30 min. Following this, cells (5×105/
ml) were washed twice with D-MEM and re-suspended
in D-MEM. The calcein-labeled cells were incubated at
37°C. After 120 min, non adherent cells were removed
by washing and fluorescence was measured with a fluor-
escein filter set (absorbance 494 nm, emission 517 nm).






























































































wild type of TNRC6B mutated type of TNRC6B
ology of the sequence between miRNA and TNRC6B. Complementary
m (upper side) and Targetscan algorithm (lower side). B) Changes in
n means ± SD of three independent experiments. Asterisk indicates a
er the wild (left part) or mutated (right part) TNRC6B 30UTR and miR-
sterisk indicates a significant difference (p < 0.05). D) Target
8b exists in RISC, compared with existence of control RNA, TNRC6B is
CR in 10 ng sample of total RNA from the Ago2-IP fraction. The data

















































Figure 2 Expression pattern of TNRC6B and miR-18b according to the histological differentiation. Expression pattern of TNRC6B and miR-
18b according to the degree of histological differentiation by real-time qPCR. Each column represents the relative amount of TNRC6B normalized
to the expression level of β-actin or the relative amount of miR-18b normalized to the expression level of U18. The data shown are means ± SD
of three independent experiments. Asterisk indicates a significant difference (p < 0.05).
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adherent cells by the total corrected fluorescence of
cells added to each well.Statistical analyses
Statistical analyses were performed using Student’s t-test;
p values less than 0.05 were considered statistically sig-
nificant. Microarray data were also statistically analyzed
using ANOVA or Welch’s test and Bonferroni correction
for multiple hypotheses testing. Survival analysis was
used with Kaplan-Meier survival curve and log-rank
tests in the R software environment.Results
Microarray analysis
miRNA expression profiles in 110 HCC were established
by microarray analysis (Table 1 and Additional file 1: Table
S1) and comprised of 60 moderately, 30 poorly, and 20
well differentiated HCC. We chose miRNAs that were
clearly expressed in at least 70% of all samples as deter-
mined by numeric analysis. Twelve miRNAs were signifi-
cantly differentially expressed depending on whether HCC
was poorly, moderately or well differentiated according to
ANOVA analysis. The expression of miR-221, miR-18a,
miR-18b, and miR-423-5p in poorly differentiated HCC
were significantly higher than in well differentiated HCC,
and 8 miRNAs (miR-455-3p, miR-1914*, miR-100, miR-215, miR-122*, let-7b, miR-22 and miR-99a) in poorly
differentiated HCC had significantly lower expression
levels than in well differentiated HCC (p < 0.05)
(Table 2).Determining miR-18b target genes
We then detected the target gene of the 12 miRNAs that
were differentially expressed according to the level of
HCC differentiation. Homo sapiens trinucleotide repeat
containing 6B (TNRC6B) was a common hypothetical
target gene in miR-221, miR-18a, miR-18b, miR-423-5p,
miR-455-3p, miR-1914*, miR-215, miR-122*, let-7b, and
miR-22 using miRanda algorithm. TNRC6B on the
other hand, was a common target gene in miR-221,
miR-18a, miR-18b, miR-423-5p, and miR-22 using
Targetscan. miR-221, miR-18a, miR-18b, miR-423-5p,
and miR-22 could recognize TNRC6B as a target gene
using both algorithms (Figure 1A)
To clarify the biological links between miRNAs and
TNRC6B, we examined the expression pattern of
TNRC6B in Huh7 cells by real-time qPCR when expres-
sion levels of miR-18a, miR-18b miR-122, miR-221,
miR-423-5p, and miR-22 were either over-expressed or
suppressed. The result was that low expression of
TNRC6B was reflected by over-expression of miR-18b
treated with mature miR-18b and vise versa when
miR-18b was suppressed with antisense oligonucleotide.
Figure 3 A) Expression of miR-18b and TNRC6B according to the degree of histological differentiation in HCC. Well differentiated HCC
showed low expression of miR-18b; poorly differentiated HCC showed strong expression of miR-18b. TNRC6B down-regulation in HCC is inversely
related to miR-18b expression. HE stain (a, d, g), in situ hybridization of miR-18b (b, e, h) and immunohistochemistry of TNRC6B (c, f, i) are shown,
respectively. Blue indicates the expression of miR-18b (arrows) and brown indicates the expression of TNRC6B (arrowheads). Bars indicate 100 μm.
B) Positive cells for miR-18b in situ hybridization and TNRC6B immunostain was quantified by each miR-18b in situ hybridization and TNRC6B
immunostain score system, respectively.
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over-expressed or suppressed was similar to the expres-
sion pattern using miR-18b (Figure 1B). However, over-
expression of miR-18a, miR-122, and miR-423-5p did
not suppress the expression level of TNRC6B and
suppression of miR-221 did not induce over-expression
of TNRC6B.
Based on our findings, we prepared the reporter gene
assay with wild or mutant sequence of the hypothetical
binding site of TNRC6B and miR-18b. When miR-18bwas co-transfected with wild type of 3′UTR of TNRC6B
reporter genes, we observed that luciferase activity was
significantly low compared to co-transfecting control
RNA or miR-18b plus ASO miR-18b with wild type vec-
tor. However, in case of the mutant form of 3’UTR of
TNRC6B reporter vector, the luciferase activity was not
affected by transfection of any miRNAs (Figure 1C).
Then, we speculated that miR-18b and miR-22 could
regulate the expression level of TNRC6B, and to clarify


























































































Figure 4 The association between miR-18b and TNRC6B expression pattern and the cell proliferation and adhesion in hepatoma cell
lines. A) Cell proliferation index in Huh7 and Li7 cells respectively, after over-expression of miR-18b or TNRC6B, or suppression of miR-18b or
TNRC6B for 24 or 72 hr. The data shown are means ± SD of three independent experiments. B) Cell adhesion index in Huh7 and Li7 cells
respectively after over-expression of miR-18b or TNRC6B, or suppression of miR-18b or TNRC6B for 24 or 72 hr. The data shown are means ± SD of
three independent experiments. Asterisk and double asterisk indicate a statistically significant difference of (p < 0.05) and (p < 0.01), respectively.
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tionated cell lysates were prepared by transfecting 293FT
cells with mature double strand of miR-18b, miR-22, miR-
455-3p, let-7b, or a non-specific siRNA which was used as
a control RNA. miR-455-3p and let-7b were used as nega-
tive controls. The TNRC6B RNA in the Ago2-IP fraction
(IP RNA) was quantified by real-time qPCR. The concen-
tration of TNRC6B IP-RNA treated with miR-18b was
higher than those treated with the control RNA or double
strand of miR-22, miR-455-3p, and let-7b (Figure 1D).
Taken together, we concluded that miR-18b can regulate
the expression of TNRC6B as a target gene.miR-18b and TNRC6B expression correspond to the
degree of histological differentiation
We compared TNRC6B expression in clinical samples
with the grade of histological differentiation. TNRC6B
expression in poorly differentiated HCC was lower than
in well differentiated HCC (Figure 2A). miR-18b con-
firmed the microarray results using real-time qPCR,
while the real-time qPCR result corresponded to the
microarray analysis result (Figure 2B). Although the
microarray and realtime qPCR results correlated, the
expression level of miRNA in both experiments differed.
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Figure 5 miR-18b expression and relapse-free rate after surgical resection in 73HCC. Kaplan–Meier curves showing the percentage of
relapse-free HCC patients after surgical resection grouped on the basis of their median miR-18b expression level.
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However, there was no significant correlation between
the contra-relation of miR-18b and TNRC6B expression.
We then performed in situ hybridization using locked
nucleic acid (LNA)-modified probes labeled with digo-
xigenin (DIG) in miR-18b and also immunohistochemis-
try of TNRC6B in 8 samples (well differentiated: case 64,
108; moderately differentiated: 248, 277, 310, 333; poorly
differentiated: case 261, 274). We found high miR-18b and
low TNRC6B expression levels in poorly differentiated
HCC (case 261), low miR-18b and high TNRC6B expres-
sion levels in highly differentiated HCC (case 64), and
moderate expression miR-18b and TNRC6B in moderately
differentiated HCC (case 248) (Figure 3A, B). The results
of the five remaining cases and scrambled LNA study are
not shown.
Aberrant expression of miR-18b and TNRC6B can modify
cell proliferation and unusual fashion of cell adhesion in
hepatoma cell lines
Over-expression of miR-18b and inhibition of TNRC6B by
siRNA in human hepatoma cell lines Huh7, showed the
progression of cell proliferation. Inhibition of TNRC6B by
siRNA in both Huh7 and Li7, showed the progression of
cell proliferation (p < 0.05) (Figure 4A). In both cell lines,
over-expression or inhibition of miR-18b showed dece-
leration or acceleration of cell adhesion respectively
(p < 0.05). Over-expression of TNRC6B by siRNA showed
acceleration of cell adhesion in Huh7 (p < 0.01); however,
over–expression of TNRC6B by siRNA also showed a
similar acceleration of cell adhesion in Li7 (Figure 4B).These results indicated that over-expression of miR-18b
and inhibition of TNRC6B, have the advantage of acceler-
ating cell proliferation and decelerating cell adhesion.
Over-expression of miR-18b in HCC is associated with
poor prognosis
We then analyzed the prognosis of 73 HCC whose pro-
gress was monitored after surgery resection. Kaplan-
Meier survival analysis and log-rank test demonstrated
a significant difference in the outcomes of patients who
were divided into two groups based on their median
miR-18b expression level (p < 0.05). Specifically, patients
with high expression of miR-18b had significantly lower
survival rate than patients with low miR-18b expression.
While miR-18b expression was associated with the
relapse-free rate after surgical resection, we found that
it did not significantly affect the overall survival rate
(Figure 5 and Additional file 1: Table S2).
Comparison between clinical background and miRNA
expression pattern
To ascertain if any connection exists between miRNA ex-
pression and clinical background, we compared miRNA
expression with tumor size, gender, age and background
of HCC. Since a 20 mm diameter tumor is standard for
liver cancer in the early stage, we compared the miRNA
expression for HCC larger than 20 mm with those smaller
than 20 mm. Three miRNAs were extracted based on two
criteria: fold change 0.5 > or 2.0<, and t-test p < 0.05. The
expression level of miR-1471 in small HCC was signifi-
cantly higher than in large HCC, and the expression level
Table 3 The relationship between several clinical factors
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cantly lower than in large HCC (Table 3).
We also identified miRNAs with expression levels that
varied according to gender and age. Namely, miR-765,
miR-622, and miR-1300 had significantly lower expression
levels in female HCC than in male HCC (Table 2). In
regards to age, we discovered that the expression levels of
14 miRNAs (miR-654-5p, miR-493*, miR-410, miR-376a*,
miR-758, miR-381, miR-543, miR-539, miR-487b, miR-337
-5p, miR-136*, miR-154*, miR-330-3p, and miR-421) were
significantly higher in HCC up to 66 years old than in
HCC over 67 years old. The average age of the HCC
subjects was 66.8 years old (Table 3).
Finally, when miRNA expression pattern was linked to
the cause of HCC, we found that the expression level of
miR-181d, miR-542-3p, and miR-519e in HCC derived
from CH was significantly higher than in HCC from liver
cirrhosis (LC). Additionally, the expression level of miR-
939 in HCC derived from CH was significantly lower than
in HCC from LC (Table 3). However, we found no signifi-
cant correlation between the expression pattern of miR-
18b and tumor size, age, gender, and background of HCC.
Discussion
In the present study we established that in HCC miRNA
was differentially expressed according to the grade of
histological differentiation, recurrence of HCC after re-
section, tumor size, HCC background, age, and gender.
In addition, we also established that over-expression of
miR-18b and down-regulation of TNRC6B was closely
associated with the proliferation of HCC. Extending our
analysis to all miRNAs made it clear that the expression
level of several miRNAs correlated with the progress
of HCC. Recent reports have asserted that when
distinguishing several diseases using miRNA profiling in
the blood, diagnostic accuracy is higher when relative
large numbers of miRNAs is used [19]. Therefore,
performing a comprehensive miRNA analysis can be a
shortcut for investigating novel biomarker for HCC.
Previously, we built a miRNA microarray based on the
miRbase ver. 5.0 and reported that miR-92, miR-20,
miR-18 and precursor miR-18 had significantly high ex-
pression in poorly differentiated HCC samples, moderate
expression in moderately differentiated HCC and low
expression in well-differentiated HCC. In contrast, miR-
99a expression exhibited a positive correlation with the
degree of tumor differentiation [9]. In the present study,
we used a miRNA microarray referenced on the miRbase
ver. 14.0 and showed that the expression of miR-221,
miR-18a, miR-18b, and miR-423-5p in poorly differenti-
ated HCC were significantly higher than in well differen-
tiated HCC, and 8 miRNAs (miR-455-3p, miR-1914*,
miR-100, miR-215, miR-122*, let-7b, miR-22 and miR-
99a) in poorly differentiated HCC were expressedsignificantly lower than in well differentiated HCC. The
expression pattern of miR-18, 22, 99, 221 in HCC
observed in this study are similar to that noted in our
previous reports [9].
Considering our miRNA profiling in HCC based on a
variety of clinical information (grade of histological dif-
ferentiation, recurrence of HCC after resection, size of
tumor, the background of liver disease, age, and gender)
and our analysis of the efficiencies of miRNAs in rela-
tion to cancer cell proliferation or adhesion, we strongly
believe that miR-18b may be the gene with the most
potential as a biomarker for diagnosing, prognosing or
elucidating molecular pathogenesis.
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http://www.biomedcentral.com/1471-2407/13/99Other studies have indicated that over-expression of both
miR-221 and miR-18a is associated with hepatocar-
cinogenesis [20,21] and that over-expression of miR-221 is
related to the advancement of tumor stages and metastasis
[22]. Down-regulation of miR-22 has proliferative effect on
HCC [23]. Prior studies using borderline tissue from
colorectal liver metastases have validated the liver
invasion front-specific down-regulation of miR-19b,
miR-194, let-7b and miR-1275, and the tumor invasion
front-specific down-regulation of miR-143, miR-145,
let-7b and miR-638 [24].
Perturbations of miRNA networks are linked to a
wide variety of pathological processes, including cardio-
vascular diseases and cancer. In this study we showed
that a) over-expression of miR-18b was associated with
poor prognosis of HCC; b) miR-18b has the ability to
control the expression of TNRC6B gene as a target; and
c) over-expression of miR-18b and down-regulation of
TNRC6B showed malignant potential for hepato-
carcinogenesis.
TNRC6B, a RNA recognition motif–containing pro-
tein, is localized to mRNA-degrading cytoplasmic P
bodies and is functionally required to mediate miRNA-
guided mRNA cleavage [25]. TNRC6B is expressed in
many normal tissues including the prostate and is more
suppressed in hormone-refractory metastatic prostate
cancer than in prostate carcinoma [26]. Polymorphism
of the promoter region of TNRC6B was also associated
with prostate cancer [27]. Alterations in TNRC6B gene
expression due to genetic variations might perturb the
levels of mRNA species normally under its control and
therefore contribute to carcinogenesis. Therefore, aber-
rant expression of TNRC6B might also contribute to
hepatocarcinogenesis. This suggests that when miR-
18b and TNRC6B are aberrantly expressed it is easy
for oncogenesis to occur. Since our study revealed
that TNRC6B did not correlate with recurrence, or
survival rate of HCC, we speculate that TNRC6B may
be regulated by a gene other than miR-18b. Detailed
analysis is required in order to reach a conclusive
decision.Conclusions
In this paper we presented the results of our miRNA
expression profiling in HCC and highlighted the clinical
and functional implications of miR-18b expres-
sion. Since down regulation of miR-18b and/or over-
expression of TNRC6B inhibited cell proliferation and
promoted cell adhesion, we propose miR-18b as a new
diagnostic and prognostic miRNA marker for HCC pro-
gression. Our study provides a rationale for the classifi-
cation and development of novel therapy for human
HCC using miRNA profiling.Additional file
Additional file 1: Table S1. Clinical background of HCC in detail. Table
S2. Information of the surgical treatment and prognosis. Table S3.
Inserter sequence of the miR-18b binding sequence of the TNRC6B 3′-
UTR for reporter vector.
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